Latest news with #PaulKim
.JPG%3Fwidth%3D780%26fit%3Dcover%26gravity%3Dfaces%26dpr%3D2%26quality%3Dmedium%26source%3Dnar-cms%26format%3Dauto&w=3840&q=100)
Nikkei Asia
6 days ago
- Entertainment
- Nikkei Asia
Paul Kim's ballad style wins fans in Southeast Asia
Arts South Korean singer-songwriter's heartfelt songs transcend social media frenzy Paul Kim, 37, entered the music industry in 2014, gaining recognition for writing and composing ballads for top South Korean dramas. (Photo by Norman Goh) NORMAN GOH KUALA LUMPUR -- For the South Korean singer-songwriter Paul Kim, music has always been more than a profession -- it began as a deeply personal outlet, a diary set to melody, and a way to process emotions too complex for words. "I was expressing myself, my feelings, my emotions through music," Kim told Nikkei Asia in an interview during a recent visit to Kuala Lumpur, where he hosted the Round 2025 ASEAN-Korea concert on June 26 and 27.
Hype Malaysia
01-07-2025
- Entertainment
- Hype Malaysia
(Photos) Korean Band Dragon Pony Shares Snapshots From Recent Visit To Malaysia
Whether it's a solo concert or a music festival, there's nothing quite like seeing your favourite artist perform live on stage in your home country. What's even more exciting is when they take the time to explore the local culture and visit popular tourist spots around the city they're performing in. In recent years, we've seen plenty of K-pop idols sharing vlogs or photos of themselves wandering around Kuala Lumpur and sampling local delicacies. Joining the list of Korean stars doing just that is rock band Dragon Pony (드래곤포니), who recently shared what they got up to during their visit to the capital. In case you missed it, Dragon Pony recently performed in Malaysia as part of the artist line-up for the KBS 2025 ROUND Festival, which took place at Zepp Kuala Lumpur from 21st (Saturday) to 22nd (Sunday) June 2025. The band took to the stage on Day 2 of the event, performing on the same day as Korean singer Paul Kim, who delighted fans with a cover of Anuar Zain's 'Sedetik Lebih'. Over the long weekend, the four-member group shared a video on their Instagram page, showing their excited reaction to receiving what appeared to be a disposable film camera. The clip then cuts to a slideshow of snapshots capturing their time together in Kuala Lumpur. As seen in the photos above, apart from the ROUND Festival itself, some of the shots capture their visit to the Petronas Twin Towers and Pavilion Kuala Lumpur in Bukit Bintang. The band also appeared to enjoy a pizza meal in the city, although the restaurant remains unidentified. Shortly after posting the video and photos on social media, Malaysian fans were thrilled to see Dragon Pony enjoying their time in Kuala Lumpur. Many expressed hopes that the band would return to Malaysia for a solo concert in the future, while others were happy that our country is featured in their social content. Some were wondering if any fans saw or approached the members while they were exploring the city. Dragon Pony have also been uploading vlogs on YouTube from the countries they've performed in recently, so here's hoping they'll share one from their time here in our beloved Malaysia. Were you there to catch the band's set at the ROUND Festival last month? Watch the video below: Sources: Instagram, Twitter What's your Reaction? +1 0 +1 0 +1 0 +1 0 +1 0 +1 0
Hype Malaysia
23-06-2025
- Entertainment
- Hype Malaysia
(Video) South Korean Singer Paul Kim Covers Anuar Zain's 'Sedetik Lebih' During Recent KL Show
Seeing your favourite K-pop idol perform live in your own country is always exciting. While it's common for artists to greet fans in the local language, it's much rarer—and more special—when they perform a song in that language, showing true respect for the culture. On 22nd June (Sunday), South Korean singer Paul Kim (폴킴) performed at the '2025 ROUND' Festival in Malaysia. Known for his heartfelt ballads, he offered a calming contrast to Dragon Pony's energetic set before him. The songwriter then surprised the audience by covering the popular Malaysian song 'Sedetik Lebih' by Anuar Zain. Known as the 'OST Prince,' Paul Kim, born Kim Tae-hyung (김태형), is a renowned songwriter in the Korean entertainment industry. Since beginning his career in 2014, he has gained recognition for his work on popular K-dramas such as 'Should We Kiss First?' and 'Hotel Del Luna.' His music stands out for its rich blend of R&B, jazz, and emotional lyrics, showcasing a wide musical palette. Recently, he was invited to perform at '2025 ROUND', a festival dedicated to spreading South Korean music across ASEAN countries. This year, Malaysia hosted the event, featuring 14 artists from across the region. As the headline performer on the second day, Paul Kim delivered a memorable set, showcasing a selection of his signature OSTs and beloved songs to the audience. During his performance, the Korean singer made a genuine effort to connect with the local crowd, letting his warm personality shine. One of the night's most memorable moments came as the lights dimmed and soft drums filled the air. The audience cheered as he began singing a segment of Anuar Zain's 'Sedetik Lebih' with clear Malay pronunciation. His emotional delivery and clear vocals showcased his talent beyond language. With that simple yet powerful gesture, the Genie Awards winner left a lasting impression on the Malaysian crowd. His ability to bridge cultures through music made his '2025 ROUND' performance truly unforgettable, securing his place in the hearts of local fans. The positive response from the audience shows how taking the time to learn and sing songs dear to locals' hearts can leave a lasting impact towards an idol. Here is Paul Kim's cover of 'Sedetik Lebih': Sources: Twitter, DramaWiki Zaima Humaira contributed to this article What's your Reaction? +1 0 +1 0 +1 0 +1 0 +1 0 +1 0
Korea Herald
07-05-2025
- Business
- Korea Herald
CHA Biotech's Matica partners with Texas A&M to accelerate CGT development
Matica Biotechnology Inc., a US subsidiary of South Korea-based biotechnology company CHA Biotech, has signed a strategic partnership agreement with the National Center for Therapeutics Manufacturing at Texas A&M University to accelerate the development of cell and gene therapies, or CGT. This collaboration merges Matica Bio's manufacturing and regulatory expertise with NCTM's early-stage research and development capabilities. The two organizations aim to provide an integrated service platform that supports CGT innovators from early research through clinical trials and commercialization — all within College Station, Texas. Matica Bio operates a state-of-the-art CGT Contract Development and Manufacturing Organization facility equipped with the Ambr 250 bioreactor and single-use systems. Its proprietary HEK293-based cell line, MatiMax, enhances production efficiency and reduces development timelines and costs. NCTM, part of the Texas A&M Engineering Experiment Station, plays a key role in supporting biotechnology research and workforce development. Through this partnership, it will offer bench-to-pilot scale support to academic labs, start-ups and biotech firms working on early-stage CGT programs. 'This partnership creates powerful synergy between academic innovation and industrial execution,' said Paul Kim, CEO of Matica Biotechnology. 'It enables faster, more cost-effective CGT development and reduces market entry barriers.' Director of NCTM Dr. Baley Reeves added, 'Our collaboration with Matica Bio will help deliver cutting-edge therapies to patients more efficiently by streamlining production and reducing costs.'
Yahoo
03-05-2025
- Business
- Yahoo
Fulgent Genetics Inc (FLGT) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
Revenue: $73.5 million in Q1 2025, compared to $76.2 million in Q4 2024. GAAP Gross Margin: 38.6%. Non-GAAP Gross Margin: 41%. GAAP Operating Expenses: $48.1 million in Q1 2025. Non-GAAP Operating Expenses: $37.4 million. Adjusted EBITDA Loss: $2.9 million in Q1 2025. Non-GAAP Income: $1.2 million, or $0.04 per share. Stock Repurchase: 646,000 shares repurchased at a cost of $10.9 million in 2025. Cash Position: $814.6 million in cash, cash equivalents, restricted cash, and marketable securities. 2025 Revenue Outlook: Core revenue expected to be approximately $310 million, representing 10% growth year over year. 2025 Non-GAAP Gross Margin Outlook: Expected to slightly exceed 40% for the full year. 2025 Non-GAAP Operating Margin Outlook: Approximately minus 15% for the year. 2025 GAAP EPS Outlook: Expected loss of approximately $1.95 per share. 2025 Non-GAAP EPS Outlook: Expected loss of $0.65 per share. End of 2025 Cash Position Outlook: Expected to be approximately $770 million. Warning! GuruFocus has detected 3 Warning Signs with FLGT. Release Date: May 02, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Fulgent Genetics Inc (NASDAQ:FLGT) reported year-over-year growth in its Laboratory Services business, indicating strong momentum in 2025. The company's Therapeutic Development pipeline is progressing well, with FID-007 in Phase 2 trials and FID-022 set to begin Phase 1 trials soon. Precision Diagnostics saw a 17.8% year-over-year increase, driven by reproductive health services and Beacon Expanded Carrier Screening. The company has successfully onboarded new VA hospitals and is seeing significant usage, indicating potential upside from new initiatives. Fulgent Genetics Inc (NASDAQ:FLGT) has a strong cash position with approximately $814.6 million in cash, cash equivalents, and marketable securities, supporting future growth and strategic initiatives. Revenue for the first quarter of 2025 was $73.5 million, a decrease from $76.2 million in the fourth quarter of 2024. Non-GAAP operating margins decreased approximately 5 percentage points sequentially to a minus 10%, primarily due to lower revenue and gross margins. The BioPharma Services business experienced a 33.7% sequential decline, reflecting the variability and timing of contracts in this segment. The company expects a non-GAAP loss of $0.65 per share for the full year 2025, indicating ongoing financial challenges. Despite strong performance in certain areas, the company did not raise its full-year guidance, suggesting caution regarding future uncertainties. Q: Why didn't Fulgent Genetics raise its full-year guidance despite strong momentum in VA contracts and Foundation Medicine? A: Paul Kim, CFO, explained that the company wants to be more comfortable before adjusting the guidance. They prefer any adjustments to be considerable rather than minor. The EPS came in better than expected, but they are monitoring the impact of aggressive stock buybacks on EPS before making any changes. Q: How much of the Q1 results in Precision Diagnostics came from new accounts versus existing business? A: Brandon Perthuis, CCO, noted that the strong performance was a mix of existing clients ordering more and new client wins. The company continues to gain market share, especially in reproductive health, and some new clients are still being onboarded, which takes time. Q: What are the plans for capital deployment in 2025, including stock buybacks and M&A? A: Ming Hsieh, CEO, stated that the company is actively deploying capital for stock buybacks and evaluating potential M&A opportunities to enhance their distribution network and deploy technologies. Q: What is the expected penetration rate for FID-107, and what is the market potential? A: Ming Hsieh, CEO, mentioned that FID-107 targets EGFR-positive patients and non-EGFR populations in head and neck cancer. The market is large, and the company is optimistic about the results and potential expansion to other options after Phase 2 trials. Q: How is Fulgent Genetics planning to expand its sales and marketing efforts? A: Paul Kim, CFO, and Brandon Perthuis, CCO, explained that the company is actively hiring salespeople across all divisions, including pediatric and rare disease testing, reproductive health, and pathology. They believe their operational capabilities will support the success of the expanded sales team. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
